You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 5,885,842


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,885,842
Title: Methods for the detection of nitric oxide in fluid media
Abstract:Non-invasive methods have been developed for the measurement of NO levels in a variety of fluid media, e.g., body fluids. The present invention embraces the use of a semi-permeable vessel wherein said vessel contains an NO reacting substance to trap NO diffusing thereinto, and a simple physical or chemical detection method to measure the levels of the end products. Since NO is a neutral gas molecule, it is capable of diffusing freely across a wide range of biocompatible polymer membranes which exhibit a high permeability to NO and other neutral gas molecules, such as O.sub.2 and CO.sub.2, but which are not permeable to charged molecules, such as NO.sub.3.sup.- or NO.sub.2.sup.-. The latter two compounds are ubiquitously present in body fluids and often interfere with the measurement of NO levels. The permeability of selected membranes to NO, but not to NO.sub.3.sup.- or NO.sub.2.sup.-, makes it possible for the bags employed in the practice of the invention to selectively collect NO, even in the presence of potentially competing species. The simple, easy and non-invasive methods of the invention will find a variety of uses, e.g., for diagnosis and monitoring of NO overproduction (and underproduction) that has been associated with many inflammatory and infectious diseases.
Inventor(s): Lai; Ching-San (Encinitas, CA)
Assignee: Medinox, Inc. (San Diego, CA)
Application Number:08/745,678
Patent Claims:1. A method for the detection of nitric oxide in liquid media, said method comprising:

providing an article comprising a nitric oxide trapping agent contained within a vessel, wherein the contents of said vessel are capable of communicating with liquid media brought into contact with said vessel via a semi-permeable membrane, wherein said semi-permeable membrane is permeable to neutral gas molecules, but is impermeable to charged molecules,

contacting liquid media suspected of containing nitric oxide with said article, wherein said contacting is carried out under conditions suitable to allow diffusion of nitric oxide in said liquid media across the semi-permeable membrane of said article, and

determining the amount of nitric oxide trapped by said nitric oxide trapping agent.

2. The method according to claim 1 wherein said liquid media is selected from the group consisting of body fluids, growth media, and industrial fluids.

3. The method according to claim 2 wherein said liquid media is a body fluid selected from the group consisting of saliva, blood, tears, urine, synovial fluid and peritoneal fluid.

4. The method according to claim 2 wherein said liquid media is a growth and maintenance medium selected from the group consisting of organ preservation media, tissue culture media, cell culture media and reperfusion media.

5. The method according to claim 2 wherein said liquid media is aqueous or non-aqueous industrial waste.

6. The method according to claim 1 wherein said nitric oxide trapping agent is selected from the group consisting of chelating agents, carboxy-2-phenyl-4,4,5,5-tetramethylimidazoline-oxyl-1-oxyl-3-oxide, nitrones, oxygen, thiol compounds, physiologically compatible aqueous media, apolar oxygenated solvents, guanylate cyclase/GTP system, superoxide anion radicals, peroxynitrite, xanthine (hypoxanthine)/xanthine oxidase system, peroxides, superoxide dismutase, antibodies directed against free radical adducts and Griess reagent.

7. The method according to claim 6 wherein said chelating agents are selected from the group consisting of metal ion-containing complexes of dithiocarbamates, hydroxamine acid siderophore ferrioxamine B and derivatives thereof, metal ion-containing complexes of diethylenetriaminepentaacetic acid, hemoglobins, cobalamin (vitamin B12) and derivatives thereof, porphyrins, heme, myoglobins and meso-2,3-dimercaptosuccinic acid.

8. The method according to claim 7 wherein said metal ions are iron, copper, cobalt, zinc or manganese ions.

9. The method according to claim 7 wherein said dithiocarbamates is selected from compounds having the structure:

wherein each R is independently a C.sub.1 up to C.sub.18 alkyl, substituted alkyl, cycloalyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, aroyl, substituted aroyl, acyl, or substituted acyl, or the two R groups can cooperate to form a 5-, 6- or 7-membered ring including N and the two R groups.

10. The method according to claim 6 wherein said thiol compounds are thiol containing amino acids, thiol containing peptides, thiol containing proteins, glutathione, thiol containing carbohydrates or thiol containing nucleotides.

11. The method according to claim 6 wherein said physiologically compatible aqueous media is selected from the group consisting of saline, sterile water, phosphate-buffered saline, culture media and balanced salt solutions.

12. The method according to claim 6 wherein said apolar oxygenated solvent is a fluorinated cycloaliphatic compound, a fluorinated aromatic compound or a fluorinated carboxylic acid.

13. The method according to claim 6 wherein said nitric oxide trapping agent is selected from the group consisting of superoxide anion radicals, peroxynitrite, xanthine (hypoxanthine)/xanthine oxidase system, peroxides and Griess reagent.

14. The method according to claim 1 wherein said vessel comprises:

a flexible bag constructed of said semi-permeable membrane; or

a rigid or semi-rigid receptacle containing said nitric oxide trapping agent, wherein said receptacle has at least one opening therein, and wherein said nitric oxide trapping agent is retained within said receptacle by said semi-permeable membrane; or

a pouch containing said nitric oxide trapping agent, wherein at least a portion of said nitric oxide trapping agent is in fluid communication with said liquid media via said semi-permeable membrane.

15. The method according to claim 1 wherein said vessel is suitable for sublingual introduction into a subject.

16. The method according to claim 1 wherein said vessel is suitable for subcutaneous introduction into a subject.

17. The method according to claim 16 further comprising surgically introducing said vessel into said subject.

18. The method according to claim 1 wherein said vessel is suitable for placing into culture media in cell culture vessels.

19. The method according to claim 1 wherein said semi-permeable membrane is prepared from one or more materials selected from the group consisting of polydiorganosiloxane, polyolefins, polyalkadienes, polyvinylbenzene, halogenated polyolefins, halogenated polyalkadienes, polycarbonates, poly(ethylene terphthalate), polyacrylates, and polyurethanes.

20. The method according to claim 19 wherein said semi-permeable membrane is prepared from one or more polydiorganosiloxanes selected from the group consisting of polydialkylsiloxane, polydiarylsiloxane, polyalkylarysiloxane, polydialkenylsiloxane, polyalkenylalkylsiloxane and polyalkenylarylsiloxane.

21. The method according to claim 19 wherein said semi-permeable membrane is a polyolefin selected from the group consisting of polypropylene, polyisobutylene, poly(propylene-CO-ethylene), poly(isobutylene-CO-isoprene) and poly(isobutylene-CO-maleic acid).

22. The method according to claim 19 wherein said semi-permeable membrane is a polyalkadiene selected from the group consisting of polybutadiene, poly(dimethyl butadiene) and polyisoprene.

23. The method according to claim 19 wherein said semi-permeable membrane is a polyvinylbenzene selected from the group consisting of polystyrene, poly(alpha-methyl styrene), poly(butadiene-styrene), poly(allyl alcohol-styrene), poly(divinylbenzene-styrene) and poly(maleic acid-styrene).

24. The method according to claim 19 wherein said semi-permeable membrane is a halogenated polyolefin or halogenated polyalkadiene selected from the group consisting of poly(vinyl chloride), polychloroprene, polytrifluorochloroethylene and polytetrafluoroethylene.

25. The method according to claim 19 wherein said semi-permeable membrane is a polyacrylate selected from group consisting of polyacrylic acid, poly(methyl methacrylate), poly(methyl methacrylate-CO-ethyl acrylate) and poly(methyl methacrylate-CO-methacrylic acid).

26. The method according to claim 1 wherein the amount of nitric oxide trapped by said article is determined by electron paramagnetic resonance spectroscopy, nuclear magnetic resonance, radioisotope tracing, UV-visible spectrophotometry, immunohistchemical methods, fluorescent methods, immunologic methods, gas chromatography, liquid chromatography, thin-layer chromatography, mass spectroscopy, liquid scintillation counting or infrared spectroscopy.

27. A method for the detection of disease state(s) or conditions(s) in a subject in whom the overproduction of nitric oxide occurs, said method comprising,

contacting liquid media from said subject with an article comprising a nitric oxide trapping agent contained within a vessel, wherein the contents of said vessel are capable of communicating with liquid media in contact with said vessel via a semi-permeable membrane, wherein said semi-permeable membrane is permeable to neutral gas molecules, but is impermeable to charged molecules, and wherein said contacting is carried out under conditions suitable to allow diffusion of nitric oxide in said liquid media across said semi-permeable membrane, and

determining the amount of nitric oxide trapped by said nitric oxide trapping agent.

28. The method according to claim 27 wherein said disease state or condition is septic shock, ischemia, administration of cytokines, over-expression of cytokines, ulcers, inflammatory bowel diseases, diabetes, arthritis, asthma, Alzeimer's disease, Parkinson's disease, multiple sclerosis, cirrhosis, allograft rejection, liver inflammation, encephalomyelitis, meningitis, pancreatitis, peritonitis, vasculitis, lymphocytic choriomeningitis, glomerulonephritis, uveitis, ileitis, renal inflammation, hemorrhagic shock, anaphylactic shock, burn, infection, hemodialysis, chronic fatigue syndrome, stroke, cancers, cardiopulmonary bypass, ischemic/reperfusion injury, inflammation, toxic shock syndrome, gastritis, adult respiratory distress syndrome, cachexia, myocarditis, autoimmune disorders, eczema, psoriasis, heart failure, heart disease, atherosclerosis, dermatitis, urticaria, cerebral ischemia, systemic lupus erythematosus, AIDS, AIDS dementia, chronic neurodegenerative disease, chronic pain, priapism, cystic fibrosis, amyotrophic lateral sclerosis, schizophrenia, neurodegenerative disorders, obesity, gastrointestinal motility disorders, hyperphagia, solid tumors, malaria, hematologic cancers, myelofibrosis, lung injury, graft-versus-host disease, head injury, CNS trauma, hepatitis, renal failure, liver disease, drug-induced lung injury, myasthenia gravis (MG) or ophthalmic diseases.

29. A method for the detection of disease state(s) which involve the underproduction of nitric oxide, said method comprising

contacting liquid media from a subject suspected of suffering such a disease state with an article comprising a nitric oxide trapping agent substantially contained within a vessel, wherein the contents of said vessel are capable of communicating with liquid media in contact with said vessel via a semi-permeable membrane, and wherein said contacting is carried out under conditions suitable to allow diffusion of nitric oxide in said liquid media across said semi-permeable membrane, and

determining the amount of nitric oxide trapped by said nitric oxide trapping agent.

30. The method according to claim 29 wherein said disease state is neonatal persistent pulmonary hypertension, pre-eclampsia, adult respiratory distress syndrome, post-angioplasty restenosis, impotence or atherosclerosis.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.